The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer
We compared the clinical efficacy of treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist alone to combined androgen blockade (CAB) with a LH-RH agonist and fiutamide. A total of 66 stage D2 prostate cancer patients were enrolled from Nov. 1992 to Mar. 1996 (n = 30: LH-RH agonist a...
| Publié dans: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 44(1998), 7 vom: 05. Juli, Seite 477-80 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , |
| Format: | Article |
| Langue: | Japanese |
| Publié: |
1998
|
| Accès à la collection: | Hinyokika kiyo. Acta urologica Japonica |
| Sujets: | English Abstract Journal Article Androgen Antagonists Antineoplastic Agents, Hormonal Gonadotropin-Releasing Hormone 33515-09-2 Flutamide 76W6J0943E |
| Résumé: | We compared the clinical efficacy of treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist alone to combined androgen blockade (CAB) with a LH-RH agonist and fiutamide. A total of 66 stage D2 prostate cancer patients were enrolled from Nov. 1992 to Mar. 1996 (n = 30: LH-RH agonist alone, n = 36 CAB). Serum PSA levels after 3 months of treatment and progression-free survival rates (Kaplan-Meier curves) were compared. Results were statistically evaluated by Wilcoxon's text. There were no differences in PSA levels between LH-RH agonist alone and CAB. Progression-free survival rates were longer in the patients treated CAB compared to LH-RH agonist alone (P = 0.041). Furthermore, in patients with poorly differentiated prostate cancers, longer survival rates were also observed with CAB (P = 0.030). However, there were no differences in high EOD (> or = 2) patients between the two treatments (P = 0.652) |
|---|---|
| Description: | Date Completed 22.10.1998 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
| ISSN: | 0018-1994 |